BLAINJECTIONINJECTABLE
Approved
Oct 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
HYRIMOZ (adalimumab-adaz) by Novartis is tumor necrosis factor receptor blocking activity [moa]. Approved for tumor necrosis factor blocker [epc]. First approved in 2018.
Drug data last refreshed 16h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYRIMOZ (adalimumab-adaz) is a monoclonal antibody TNF-receptor blocker approved in October 2018 for autoimmune inflammatory conditions. It works by inhibiting tumor necrosis factor signaling to reduce inflammation and immune-mediated disease activity. The product is indicated for TNF-driven autoimmune disorders, predominantly rheumatoid arthritis and related conditions.
Peak
HYRIMOZ is in peak commercial phase with moderate competitive pressure (30/100), indicating a mature product supporting mid-sized commercial teams focused on market share defense rather than growth.
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Observational Study, to Assess Treatment Retention of an Adalimumab Biosimilar (Hyrimoz®) in IBD Patients in Real Life Setting
Started Feb 2023
562 enrolled
Inflammatory Bowel Disease
Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Started Jun 2019
63 enrolled
Crohn´s Disease
Career Relevance
HYRIMOZ offers career opportunities in mature product management, market defense, and payer negotiation rather than growth or innovation roles. The competitive landscape and peak lifecycle stage suggest roles focused on customer retention, biosimilar positioning, and margin optimization.
Worked on HYRIMOZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.